Euro Pacific Canada has upgraded Sophiris Bio (NASDAQ:SPHS) to “buy” from “hold” and raised its price target to $6 from $1 after the company reported positive one-year efficacy data from a Phase 3 study of PRX-302 in...
Stifel has initiated coverage of Strongbridge Biopharma plc (NASDAQ:SBBP), formerly Cortendo plc, with a “buy” rating and a $21 target price. The stock closed at $7.49 on Monday.Strongbridge is an endocrinology-focused...
Roth Capital Partners has upgraded Cogentix Medical (NASDAQ:CGNT) to “buy” from “neutral” and raised its target price to $3 from $1.85. The stock closed at $1.52 on Wednesday.“Given our confidence for Cogentix to...
Third quarter revenue for TearLab (NASDAQ:TEAR; TSX:TLB) rose 27% to $6.6-million from $5.2-million a year ago. A net total of 228 TearLab systems were added in the third quarter.“We delivered a strong growth quarter...
William Blair has launched coverage of Aclaris Therapeutics (NASDAQ:ACRS) with an “outperform” rating and $30 price target. The stock closed at $14.38 on Friday.Aclaris’ lead program, A-101, is a topical solution being...
Avivagen (TSX-V:VIV) has signed an agreement with the Bloom Burton Healthcare Lending Trust for a secured drawdown credit facility of up to $1.8-million.The facility will advance Avivagen’s plans for commercializing its...
H.C. Wainwright analyst Swayampakula Ramakanth has assumed coverage of CASI Pharmaceuticals (NASDAQ:CASI) with a “buy” rating and $3 price target. The stock closed at $1.21 on Wednesday.CASI is a clinical-stage company...
Maxim Group has initiated coverage of Rock Creek Pharmaceuticals (NASDAQ:RCPI) with a “buy” rating and 12-month price target of $4. The stock closed at 83 cents on Monday.Rock Creek’s lead product, anatabine citrate...
Feltl & Co. has launched coverage of Viking Therapeutics (NASDAQ:VKTX) with a “strong buy” rating and price target of $17.50. The stock closed at $6.90 on Wednesday.“We anticipate the company executing on multiple...
H.C. Wainwright has initiated coverage of Prima BioMed (NASDAQ:PBMD) with a “buy” rating and $3 price target. The stock closed at $1.22 on Tuesday.Australia-based Prima is developing novel checkpoint modulators (CPMs)...
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsACCEPT
Privacy & Cookies Policy
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.